Porta-Etessam, J., González-García, N., Guerrero, Á., & García-Azorín, D. (2021). Failure of monoclonal antibodies against CGRP or its receptor does not imply lack of efficacy of other drugs from the same class. Neurología (Barcelona, English ed. ), 36(8), 638-640. https://doi.org/10.1016/j.nrleng.2020.10.008
Citácia podle Chicago (17th ed.)Porta-Etessam, J., N. González-García, Á.L Guerrero, a D. García-Azorín. "Failure of Monoclonal Antibodies Against CGRP or Its Receptor Does Not Imply Lack of Efficacy of Other Drugs from the Same Class." Neurología (Barcelona, English Ed. ) 36, no. 8 (2021): 638-640. https://doi.org/10.1016/j.nrleng.2020.10.008.
Citácia podľa MLA (8th ed.)Porta-Etessam, J., et al. "Failure of Monoclonal Antibodies Against CGRP or Its Receptor Does Not Imply Lack of Efficacy of Other Drugs from the Same Class." Neurología (Barcelona, English Ed. ), vol. 36, no. 8, 2021, pp. 638-640, https://doi.org/10.1016/j.nrleng.2020.10.008.